Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Pfizer Global Research & Development
Woman and Man Max 99 years
Pfizer Global Research & Development
Update Il y a 4 ans
A 1-Year Open-Label Safety Extension Study of Pregabalin (CI-1008) in Patients With Anxiety Disorders
Main objective : • To evaluate under open-label conditions the long-term safety and tolerability of pregabalin in doses ranging from 150 to 600 mg/day.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Global Research & Development
Update Il y a 4 ans
A DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-00915275 AFTER ORAL ADMINISTRATION TO SUBJECTS WITH TYPE 2 DIABETES MELLITUS FOR 4-WEEKS
• To evaluate the effects of an oral dose of PF-00915275 (10 mg) on 24 hour mean daily glucose levels when administered as tablets for 4-weeks in subjects with T2DM.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Global Research & Development
Update Il y a 4 ans
A Placebo-Controlled Study of Pregabalin in Elderly Patients With Generalized Anxiety Disorder
1. To evaluate the efficacy of pregabalin versus placebo in relieving the symptoms of Generalized Anxiety Disorder as measured by Hamilton Anxiety Rating Scale (HAM-A) 2. Evaluate the safety of pregab...
Country
None
organs
None
Specialty
None
Closed trial
More information